BCYC
BCYCHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeOperating under the Biotechnology umbrella, BCYC is a healthcare company. Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Valued at $292.6M, BCYC is a micro-cap name in its sector. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Market Cap
$292.6M
Beta
1.54
P/E (TTM)
—
P/E (Fwd)
-1.88
EPS (TTM)
$-2.73
EPS (Fwd)
$-2.22
ROE
-32.3%
ROA
-17.9%
Cash
$510.1M
Total Debt
$14.7M
Free CF
-$99.8M
52W Change
-39.6%
Annual Financials
Cash vs Debt
Where BCYC stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, BCYC finished 8.77% below its 150-day moving average ($4.79) and 17.55% below its 200-day moving average ($5.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCYC overbought or oversold?
At the August 24, 2026 close, BCYC's RSI(14) was 73.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
BCYC holds $510.1M in cash against $14.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$99.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -32.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $11.7M (2021) to $72.6M (2025), reflecting a 521% increase over the period.
BCYC's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing BCYC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.